It has been known for more than 60 years, and suspected for over 100, that alveolar hypoxia
causes pulmonary vasoconstriction by means of mechanisms local to the lung. For the last …

Recent insights into the bioactivation and signaling actions of inorganic, dietary nitrate and
nitrite now suggest a critical role for the microbiome in the development of cardiac and …

Pulmonary vascular remodelling is an important pathological feature of pulmonary
hypertension, leading to increased pulmonary vascular resistance and reduced compliance …

Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of
pulmonary hypertension. This study was designed to investigate chronic effects of sildenafil …

IN 1998, the World Health Organization sponsored a symposium on pulmonary
hypertension at which a new, more clinically useful classification system was adopted. § …

Nitric oxide (NO) is formed enzymatically from l‐arginine in the presence of nitric oxide
synthase (NOS). Nitric oxide is generated constitutively in endothelial cells via sheer stress …

Hypoxic pulmonary vasoconstriction (HPV) serves to optimize ventilation–perfusion
matching in focal hypoxia and thereby enhances pulmonary gas exchange. During global …

Advances in the understanding of nitric oxide as a biological mediator and a therapeutic tool
continue to accumulate at a rapid rate. This review provides an update on recent …

Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by increased
pulmonary artery pressures. Long standing pulmonary arterial pressure overload leads to …

Prolonged exposure to alveolar hypoxia induces physiological changes in the pulmonary
vasculature that result in the development of pulmonary hypertension. A hallmark of hypoxic …